{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-384430","form_type":"8-K","ticker":"VERU","cik":"0000863894","company_name":"VERU INC.","filed_at":"2026-09-08T12:17:06+00:00","discovered_at":"2026-09-08T12:20:00.419958+00:00","generated_at":"2026-09-08T12:20:13.913841+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Veru pivots sabizabulin to daraxonrasib-resistant pancreatic cancer; drops cardiovascular program","bullets":["Sabizabulin showed potent activity (IC50=18.2nM) in daraxonrasib-resistant KRAS pancreatic cancer cells; resistance index 0.25 vs 68 for daraxonrasib.","Company plans Phase 2b trial in daraxonrasib-resistant metastatic pancreatic cancer; pre-IND meeting with FDA in Q4 2026.","Veru will no longer explore sabizabulin for atherosclerotic cardiovascular disease inflammation; IP protection until 2043.","Prior Phase 1b/2 data in 80 prostate cancer patients: median rPFS 11.4 months, ORR 20.7% at 63 mg daily dosing.","Enobosarm obesity program on track: PLATEAU Phase 2b fully enrolled, interim analysis Q1 2027; Novo Nordisk supply deal."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-384430","json":"https://secwatch.observer/filing/0001193125-26-384430.json","markdown":"https://secwatch.observer/filing/0001193125-26-384430.md","text":"https://secwatch.observer/filing/0001193125-26-384430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/863894/000119312526384430/0001193125-26-384430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/863894/000119312526384430/d543118d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T12:20:13.913841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}